How it works, simply
It activates GIP and GLP-1 receptors, helping regulate blood sugar and appetite.
What the evidence tells us
Trials of the approved products do not establish the quality of a separately purchased research vial.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Gastrointestinal effects and dehydration are important concerns; hypoglycemia risk increases with certain diabetes medicines.
- The label has a thyroid C-cell tumor boxed warning and specific contraindications; the human tumor risk is uncertain.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Selectively activates GIP and GLP-1 receptors.
Sponsor or developer: Eli Lilly and Company
Studied or labeled topics: Type 2 diabetes, Chronic weight management
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: ZEPBOUND prescribing information ↗ · Regulator · Sep 02, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.